title: Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.
authors.affiliation: Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, Pennsylvania, USA. saraward@temple.edu
authors.forename: Sara Jane
authors.initials: SJ
authors.lastname: Ward
authors.forename: Robert B
authors.initials: RB
authors.lastname: Raffa
mesh_terms: D000818:Animals; D001067:Appetite Depressants / Q000009:adverse effects / Q000627:therapeutic use*; D063385:Cannabinoid Receptor Modulators / Q000037:antagonists & inhibitors*; D020372:Dexfenfluramine / Q000009:adverse effects / Q000627:therapeutic use*; D015195:Drug Design; D054314:Drug Inverse Agonism; D006801:Humans; D009765:Obesity / Q000188:drug therapy; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors*; D000077285:Rimonabant; D017366:Serotonin Receptor Agonists / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D001067:Appetite Depressants; D063385:Cannabinoid Receptor Modulators; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D017366:Serotonin Receptor Agonists; D020372:Dexfenfluramine; D000077285:Rimonabant